Leslie L. Citrome, M.D., M.P.H., is a distinguished life fellow of the American Psychiatric Association and a fellow of the American Society of Clinical Psychopharmacology, where he currently serves as immediate past president. He is a volunteer consultant to the Assertive Community Treatment team/Mental Health Association of Rockland County. In 2019, Dr. Citrome received the New York Medical College Faculty Author Award for “First Authorship Who Published in the Most Open Access Journals (Web of Science)”. In 2018, 2021, and 2023, Dr. Citrome was recognized as the Voluntary Faculty Teacher of the Year in the Department of Psychiatry and Behavioral Sciences at New York Medical College/Westchester Medical Center.

Dr. Citrome is currently a consultant in clinical trial design and interpretation. He is a frequent lecturer on the quantitative assessment of clinical trial results, including the metrics of the number needed to treat and the number needed to harm, and has lectured throughout the Americas, Europe, Asia, and Australia. Dr. Citrome’s main interests include schizophrenia, bipolar disorder, and major depressive disorder. He is an author and co-author of more than 600 research reports, reviews, and chapters in the scientific literature. He is a member of the Board of Directors of the World Association of Medical Editors. Dr. Citrome is editor-in-chief of Current Medical Research and Opinion (CMRO) published by Taylor & Francis; psychiatry topic editor for Clinical Therapeutics; editor for the American Society of Clinical Psychopharmacology Corner in the Journal of Clinical Psychiatry; and also serves as an editorial board member for 11 other journals.

Education

• D.C.S., Pure and Applied Science, Dawson College
• M.D., McGill University Faculty of Medicine
• M.P.H., Columbia University School of Public Health
• Residency, Psychiatry, New York University

Publications

• Citrome L, Such P, Yildirim M, et. al. "Plain Language Summary of Publication: A comparison of once-monthly and once-every-2-months injectable formulations of aripiprazole in people with schizophrenia." Therapeutic advances in psychopharmacology, 14(), (2024) 20451253241286319. doi: 10.1177/20451253241286319
• Kaul I, Sawchak S, Claxton A, et. al. "Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials." Schizophrenia (Heidelberg, Germany), 10(1), (2024) 102. doi: 10.1038/s41537-024-00525-6
• Correll CU, Rubio JM, Citrome L, et. al. "Introducing S.C.O.P.E.™ (Schizophrenia Clinical Outcome Scenarios and Patient-Provider Engagement), an Interactive Digital Platform to Educate Healthcare Professionals on Schizophrenia Care." Neuropsychiatric disease and treatment, 20(), (2024) 1995-2010. doi: 10.2147/NDT.S477674
• Citrome L, Suett M, Franzenburg KR, et. al. "TV-46000, A Long-Acting Subcutaneous Antipsychotic Agent, Demonstrated Improved Patient-Centered Outcomes in Patients with Schizophrenia." Neuropsychiatric disease and treatment, 20(), (2024) 1901-1917. doi: 10.2147/NDT.S459104
• Seo S, Healey BE, McLin R, et. al. "Impact of Demographics and Insurance Coverage on Schizophrenia Treatment and Healthcare Resource Utilization Within an Integrated Healthcare System." Neuropsychiatric disease and treatment, 20(), (2024) 1837-1848. doi: 10.2147/NDT.S473492
• Doane MJ, Boeri M, Vass C, et. al. "Preferences for attributes of oral antipsychotic treatments: results from a discrete-choice experiment in respondents with schizophrenia or bipolar I disorder." BMC psychiatry, 24(1), (2024) 605. doi: 10.1186/s12888-024-06034-1
• Citrome L, Álvarez-Barón E, Gabarda-Inat I, et. al. "The specific anti-hostility effect of lurasidone in patients with an acute exacerbation of schizophrenia: results of pooled post hoc analyses in adolescents and adults." International clinical psychopharmacology, (), (2024) . doi: 10.1097/YIC.0000000000000563

View All Publications

Memberships and Affiliations

• Distinguished Life Fellow of the American Psychiatric Association
• Fellow of the American Society of Clinical Psychopharmacology
• Fellow (Emeritus), Collegium Internationale Neuro-Psychopharmacologicum (CINP)